Date: 2014-05-30
Type of information: R&D agreement
Compound: ProteoStat® products for antibody-drug conjugate (ADC) design
Company: Enzo Biochem (USA - NY) Innate Pharma (France)
Therapeutic area: Technology - Services
Type agreement: R&D
Action mechanism:
Disease:
Details: * On May 30, 2014, Enzo Biochem, a vertically integrated biosciences and clinical laboratory company,announced that its Life Sciences division has established a collaboration with Innate Pharma to support a novel application of its ProteoStat® products for antibody-drug conjugate (ADC) design. Innate Pharma, a biopharmaceutical company based in France, specializes in the development of new monoclonal antibodies targeting cancer and inflammatory diseases. Its long history in the generation of these antibodies positions them to enter the field of ADCs, where they have developed a unique coupling technology. Early on in the development process, Innate Pharma recognized the need for reliable methods to evaluate the stability of these ADC products in aqueous liquid form. Long-term stability was critical for validating the technology concept for clinical applications. As such, Innate Pharma looked to Enzo Life Sciences to provide assays for screening the stability and aggregation properties of their ADCs.
Financial terms:
Latest news:
